See more : Astra Exploration Inc. (ASTR.V) Income Statement Analysis – Financial Results
Complete financial analysis of FibroGen, Inc. (0IL8.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of FibroGen, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Courtside Group, Inc. Common Stock (PODC) Income Statement Analysis – Financial Results
- Shinhung Co., Ltd (004080.KS) Income Statement Analysis – Financial Results
- Net Protections Holdings, Inc. (7383.T) Income Statement Analysis – Financial Results
- Looks Health Services Limited (LOOKS.BO) Income Statement Analysis – Financial Results
- FLEX LNG Ltd. (FLNG) Income Statement Analysis – Financial Results
FibroGen, Inc. (0IL8.L)
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 147.75M | 140.73M | 235.31M | 176.32M | 256.58M | 212.96M | 125.67M | 179.58M | 180.83M | 137.60M | 102.17M | 65.93M |
| Cost of Revenue | 18.85M | 20.28M | 12.87M | 8.87M | 1.15M | 235.84M | 196.52M | 187.21M | 214.09M | 150.79M | 85.71M | 74.22M |
| Gross Profit | 128.90M | 120.45M | 222.44M | 167.45M | 255.43M | -22.88M | -70.85M | -7.63M | -33.26M | -13.19M | 16.46M | -8.29M |
| Gross Profit Ratio | 87.24% | 85.59% | 94.53% | 94.97% | 99.55% | -10.74% | -56.38% | -4.25% | -18.39% | -9.59% | 16.11% | -12.57% |
| Research & Development | 282.86M | 296.79M | 387.04M | 252.92M | 209.27M | 235.84M | 196.52M | 187.21M | 214.09M | 150.79M | 85.71M | 74.22M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 63.81M | 51.76M | 46.03M | 44.36M | 36.91M | 24.41M | 18.93M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 115.25M | 124.69M | 123.93M | 106.41M | 135.48M | 63.81M | 51.76M | 46.03M | 44.36M | 36.91M | 24.41M | 18.93M |
| Other Expenses | 12.61M | 0.00 | 0.00 | 0.00 | 0.00 | 42.16M | 0.00 | 0.00 | 0.00 | 16.00K | 156.00K | 181.00K |
| Operating Expenses | 398.11M | 421.48M | 510.97M | 359.33M | 344.74M | 299.65M | 248.28M | 233.23M | 258.45M | 187.70M | 110.12M | 93.16M |
| Cost & Expenses | 429.57M | 441.76M | 523.84M | 368.20M | 345.89M | 299.65M | 248.28M | 233.23M | 258.45M | 187.70M | 110.12M | 93.16M |
| Interest Income | 10.48M | 7.60M | 1.01M | 5.55M | 15.55M | 11.57M | 6.43M | 2.63M | 3.12M | 1.69M | 3.55M | 4.40M |
| Interest Expense | 15.53M | 1.44M | 2.15M | 2.40M | 2.88M | 10.99M | 9.71M | 10.73M | 11.03M | 11.11M | 10.70M | 10.03M |
| Depreciation & Amortization | 9.93M | 10.60M | 14.81M | 22.05M | 21.45M | 6.56M | 6.10M | 6.04M | 5.68M | 4.47M | 5.08M | 5.60M |
| EBITDA | -261.41M | -282.83M | -274.80M | -164.28M | -52.31M | -68.56M | -104.75M | -44.99M | -68.83M | -43.93M | 843.00K | -17.05M |
| EBITDA Ratio | -176.92% | -200.96% | -122.62% | -105.68% | -28.75% | -35.28% | -92.45% | -25.05% | -41.20% | -31.92% | 0.83% | -25.86% |
| Operating Income | -281.82M | -301.03M | -288.53M | -191.88M | -89.31M | -86.69M | -122.61M | -53.65M | -77.63M | -50.10M | -7.95M | -27.22M |
| Operating Income Ratio | -190.74% | -213.90% | -122.62% | -108.83% | -34.81% | -40.71% | -97.57% | -29.88% | -42.93% | -36.41% | -7.78% | -41.29% |
| Total Other Income/Expenses | -5.05M | 6.16M | -2.15M | 2.95M | 12.67M | 577.00K | -3.27M | -8.10M | -7.91M | -9.40M | -6.99M | -5.45M |
| Income Before Tax | -286.87M | -294.87M | -290.68M | -188.93M | -76.64M | -86.12M | -125.88M | -61.75M | -85.54M | -59.50M | -14.94M | -32.67M |
| Income Before Tax Ratio | -194.15% | -209.52% | -123.53% | -107.15% | -29.87% | -40.44% | -100.17% | -34.39% | -47.30% | -43.24% | -14.63% | -49.55% |
| Income Tax Expense | 3.00K | 358.00K | 347.00K | 360.00K | 328.00K | 304.00K | 321.00K | -71.00K | 242.00K | 11.12M | 10.86M | -100.00K |
| Net Income | -284.23M | -295.23M | -291.03M | -189.29M | -76.97M | -86.42M | -126.20M | -61.68M | -85.78M | -59.50M | -14.94M | -32.57M |
| Net Income Ratio | -192.37% | -209.78% | -123.68% | -107.36% | -30.00% | -40.58% | -100.43% | -34.35% | -47.44% | -43.24% | -14.63% | -49.40% |
| EPS | -2.92 | -3.15 | -3.15 | -2.11 | -0.89 | -1.03 | -1.73 | -0.98 | -1.42 | -3.17 | -0.32 | -0.69 |
| EPS Diluted | -2.92 | -3.15 | -3.15 | -2.11 | -0.89 | -1.03 | -1.73 | -0.98 | -1.42 | -3.17 | -0.32 | -0.69 |
| Weighted Avg Shares Out | 97.30M | 93.58M | 92.35M | 89.85M | 86.63M | 84.06M | 72.99M | 62.74M | 60.34M | 18.78M | 47.28M | 47.28M |
| Weighted Avg Shares Out (Dil) | 97.30M | 93.58M | 92.35M | 89.85M | 86.63M | 84.06M | 72.99M | 62.74M | 60.34M | 18.78M | 47.28M | 47.28M |
Source: https://incomestatements.info
Category: Stock Reports